Special Issue

Novel COVID-Related Antiinflammatory Drugs

Message from the Guest Editor

The COVID-19 pandemic will continue to infect a large portion of the world's population and cause substantial morbidity and mortality until either an effective vaccine or a useful antiviral therapeutic is developed. To date. potential vaccines have a long lead time, and their potential efficacy is uncertain given past failures with coronavirus vaccines. Furthermore, there is no approved antiviral therapy for COVID-19 infection. Therefore, alternative approaches must be explored in the hope of diminishing the potential consequences of COVID-19. Since many patients with COVID-19 show a massive cytokine release ("cytokine storm"), anti-inflammatory drugs have been suggested as potential treatments. This Special Issue of *Molecules* focuses on antiinflammatory approaches to treat the immune dysregulation in COVID-19.

Guest Editor

Prof. Dr. Christian Lehmann

Department of Anesthesia, Pain Management & Perioperative Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada

Deadline for manuscript submissions

closed (31 October 2022)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/119245

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/ molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

